Arbutus Biopharma Corporation develops treatments for chronic Hepatitis B virus, SARS-CoV-2, and other coronaviruses in the United States with a product pipeline including AB-729 and AB-836 for HBV. The company also has research programs to develop antiviral medicines to treat coronaviruses, including COVID-19. They have collaborative agreements with various companies, including Vaccitech plc and Alnylam Pharmaceuticals, Inc.